Journal: Infectious Diseases of Poverty

Article Title: Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes

doi: 10.1186/s40249-018-0446-z

Figure Lengend Snippet: Conceptual Framework of elimination by ivermectin treatment (used by OEPA)

Article Snippet: The registration in 1987 of ivermectin, a safe and effective microfilaricide suitable for mass treatment of onchocerciasis and given free of charge by the manufacturer, Merck & Co, led to the creation of new onchocerciasis control programmes to cover the rest of Africa outside the OCP through the African Programme for Onchocerciasis Control (APOC) and the Americas through the Onchocerciasis Elimination Programme for the Americas (OEPA) [ , ].

Techniques:

Journal: Infectious Diseases of Poverty

Article Title: Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes

doi: 10.1186/s40249-018-0446-z

Figure Lengend Snippet: Conceptual Framework of elimination by ivermectin treatment (APOC)

Article Snippet: The registration in 1987 of ivermectin, a safe and effective microfilaricide suitable for mass treatment of onchocerciasis and given free of charge by the manufacturer, Merck & Co, led to the creation of new onchocerciasis control programmes to cover the rest of Africa outside the OCP through the African Programme for Onchocerciasis Control (APOC) and the Americas through the Onchocerciasis Elimination Programme for the Americas (OEPA) [ , ].

Techniques:

Journal: PLoS Neglected Tropical Diseases

Article Title: The Global Programme to Eliminate Lymphatic Filariasis: Health Impact after 8 Years

doi: 10.1371/journal.pntd.0000317

Figure Lengend Snippet: Cumulative totals of donated drugs (Panel A), albendazole and ivermectin (Mectizan), and purchased drug (Panel B) DEC, used in GPELF between 2000 and 2007.

Article Snippet: Though Mectizan (ivermectin) has formal regulatory approval only for lymphatic filariasis and onchocerciasis and is donated by Merck & Co., Inc. only for those indications, each year millions of children and women-of-childbearing-age are concomitantly treated for debilitating intestinal parasite infections (without additional cost or effort) while participating in their national programs to eliminate LF .

Techniques:

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Use of High-Dose, Twice-Yearly Albendazole and Ivermectin to Suppress Wuchereria bancrofti Microfilarial Levels

doi: 10.1086/657063

Figure Lengend Snippet: Reduction of circulating antigen levels (CAg) after high-dose, twice-yearly albendazole and ivermectin ( A ), compared with standard-dose, annual treatment ( B ). Each solid line represents the percentage of pretreatment microfilarial level for an individual

Article Snippet: This distinction is particularly important from an economic standpoint, because albendazole and ivermectin are donated by Merck and GlaxoSmithKline, respectively, whereas the cost of drug distribution is borne by the lymphatic filariasis elimination programs themselves.

Techniques:

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Use of High-Dose, Twice-Yearly Albendazole and Ivermectin to Suppress Wuchereria bancrofti Microfilarial Levels

doi: 10.1086/657063

Figure Lengend Snippet: Reduction of Mansonella perstans microfilarial levels after high-dose, twice-yearly albendazole and ivermectin ( A ), compared with standard-dose, annual treatment ( B ). Each solid line represents the percentage of pretreatment microfilarial levels for an

Article Snippet: This distinction is particularly important from an economic standpoint, because albendazole and ivermectin are donated by Merck and GlaxoSmithKline, respectively, whereas the cost of drug distribution is borne by the lymphatic filariasis elimination programs themselves.

Techniques:

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Use of High-Dose, Twice-Yearly Albendazole and Ivermectin to Suppress Wuchereria bancrofti Microfilarial Levels

doi: 10.1086/657063

Figure Lengend Snippet: Clearance of microfilaremia after high-dose, twice-yearly albendazole and ivermectin, compared with standard-dose annual treatment. The bars represent the percentage of patients with detectable Wuchereria bancrofti microfilariae at baseline and 6, 12,

Article Snippet: This distinction is particularly important from an economic standpoint, because albendazole and ivermectin are donated by Merck and GlaxoSmithKline, respectively, whereas the cost of drug distribution is borne by the lymphatic filariasis elimination programs themselves.

Techniques:

Journal: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

Article Title: Use of High-Dose, Twice-Yearly Albendazole and Ivermectin to Suppress Wuchereria bancrofti Microfilarial Levels

doi: 10.1086/657063

Figure Lengend Snippet: Reduction of microfilaremia after high-dose, twice-yearly albendazole and ivermectin ( A ), compared with standard-dose annual treatment ( B ). Each symbol represents the value for an individual patient. The horizontal line indicates the geometric mean for

Article Snippet: This distinction is particularly important from an economic standpoint, because albendazole and ivermectin are donated by Merck and GlaxoSmithKline, respectively, whereas the cost of drug distribution is borne by the lymphatic filariasis elimination programs themselves.

Techniques: